A WHO Guideline Development Group of international experts in the British Medical Journal (BMJ) BMJ said that almost all well-informed patients would not choose to receive sotrovimab or casirivimab-imdevimab.
News Today | First with the news
News Today | First with the news
A WHO Guideline Development Group of international experts in the British Medical Journal (BMJ) BMJ said that almost all well-informed patients would not choose to receive sotrovimab or casirivimab-imdevimab.